Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
COPD
Biotech
Windward breezes toward phase 3 with $165M for TSLP ambitions
The cash infusion is meant to accelerate the development of the company’s lead candidate, a twice-yearly anti-TSLP antibody, into phase 3.
Angus Liu
May 4, 2026 10:31am
AstraZeneca’s COPD hits breathe life into class rocked by flops
Mar 27, 2026 5:58am
AirNexis swoops in with $200M series A for COPD asset
Jan 9, 2026 11:01am
Spiro Medical snares $67M series A funding for asthma treatment
Jan 8, 2026 10:50am
Roche pens $1B deal for respiratory bispecific from China
Oct 30, 2025 5:04am
Study sees COPD patients' breathing boosted by hands-free device
Mar 10, 2023 4:30pm